Evidence map›Paper›PMID 37283762›Full record

ArticleFrontiers in immunology2023

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer.

Chao Xu, Wen Zou, Lei Zhang, Ran Xu, Yuan Li, Yeqian Feng, Runtian Zhao, Yinhuai Wang, Xianling Liu, Jingjing Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Chao XuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Wen ZouDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Lei ZhangDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha, China.
Ran XuDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha, China.
Yuan LiDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha, China.
Yeqian FengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Runtian ZhaoDepartment of Oncology, Guilin Hospital of the Second Xiangya Hospital, Central South University, Guilin, China.
Yinhuai WangDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha, China.
Xianling LiuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Jingjing WangDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recent developments in MIBC treatment suggest good efficacy of bladder sparing treatment combined with immune checkpoint inhibitor. However, there is no standard treatment mode. A retrospective analysis was conducted to reveal the efficacy and safety of PD-1 inhibitor in combination with radiotherapy or chemoradiotherapy. Methods: We retrospectively analyzed 25 patients with MIBC T2-T3N0M0 disease who were unfit or unwilling to undergo RC. These patients underwent the maximum TURBT followed by PD-1 inhibitor (Tislelizumab or Toripalimab) in combination with radiotherapy or chemoradiotherapy (gemcitabine plus cisplatin) between April 2020 and May 2022. The primary outcome was clinical complete response (cCR) rate. The secondary outcomes were disease free survival (DFS) and overall survival (OS). Results: Revised: Of 25 patients, 22 were T2 (88%), while 3 were T3 (12%). The median age is 65 years (51-80). Twenty-one patients had programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or more, and 4 patients had CPS<1 or unknown. Sixteen patients received chemoradiotherapy. Tislelizumab and Toripalimab were administered to 19 and 6 patients, respectively. The median number of cycles of immunotherapy was 8. Twenty-three patients (92%) achieved cCR. Following a median of 13 months of follow-up (range, 5-34 months), 1-year DFS and OS rate were 92% and 96%, respectively. In the univariate analysis, T stage significantly influenced OS and ORR, and efficacy evaluation significantly influenced OS, DFS, and ORR. The expression of PD-L1 and chemotherapy had no effect on prognosis. In the multivariate analysis, no independent prognostic factors were found. Grade 3 or 4 adverse events (AE) were reported in 35.7% patients. Conclusions: Bladder sparing therapy with PD-1 inhibitor in combination with radiotherapy or chemoradiotherapy is feasible, safe, and highly effective for patients who were unfit or unwilling to undergo RC.

Indexed as

Immune Checkpoint InhibitorsUrinary Bladder NeoplasmsAgedAged, 80 and overB7-H1 AntigenChemoradiotherapyCisplatinHumansMiddle AgedMusclesRetrospective StudiesUrinary BladderB7-H1 AntigenCisplatinImmune Checkpoint Inhibitorsbladder cancerbladder-sparing treatmentmuscle-invasive bladder urothelial cancerprogrammed cell death protein-1 inhibitorsradiotherapy

Identifiers

PMID37283762
PMCPMC10239884
OpenAlexW4377294921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.